Mark J. Tarr
Known title: President & CEOCIK: 0001304057
Associated companies
Transaction History
| EHC | ▼ Sell | Open Market | 171,569 | $21.5M | 8/10/2026 | View on chart |
| EHC | ▼ Sell | Open Market | 1,579 | $199K | 8/10/2026 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 2,187 | $236K | 2/28/2026 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 2,488 | $264K | 2/23/2026 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 1,797 | $191K | 2/20/2026 | View on chart |
| EHC | ▲ Buy | Grant | 12,796 | $0 | 2/19/2026 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 43,378 | $4.6M | 2/19/2026 | View on chart |
| EHC | ▲ Buy | Grant | 100,946 | $0 | 2/18/2026 | View on chart |
| EHC | ▼ Sell | Open Market | 16,216 | $1.8M | 2/11/2026 | View on chart |
| EHC | ▼ Sell | Open Market | 13,231 | $1.4M | 2/11/2026 | View on chart |
| EHC | ▼ Sell | Open Market | 15,584 | $1.7M | 2/11/2026 | View on chart |
| EHC | ▼ Sell | Open Market | 10,954 | $1.2M | 2/11/2026 | View on chart |
| EHC | ▼ Sell | Open Market | 6,057 | $678K | 2/11/2026 | View on chart |
| EHC | ▼ Sell | Open Market | 87,745 | $9.9M | 2/11/2026 | View on chart |
| EHC | ▼ Sell | Open Market | 213 | $24K | 2/11/2026 | View on chart |
| EHC | ▲ Buy | Option Exercise | 56,306 | $2.0M | 5/20/2025 | View on chart |
| EHC | ▲ Buy | Option Exercise | 62,078 | $2.8M | 5/20/2025 | View on chart |
| EHC | ▼ Sell | Open Market | 94 | $11K | 5/20/2025 | View on chart |
| EHC | ▼ Sell | Open Market | 118,290 | $14.4M | 5/20/2025 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 2,187 | $219K | 2/28/2025 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 2,896 | $291K | 2/25/2025 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 2,488 | $243K | 2/24/2025 | View on chart |
| EHC | ▲ Buy | Grant | 12,152 | $0 | 2/20/2025 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 31,609 | $2.9M | 1/1/2025 | View on chart |
| EHC | ▲ Buy | Option Exercise | 19,460 | $697K | 4/30/2024 | View on chart |
| EHC | ▲ Buy | Option Exercise | 25,516 | $741K | 4/30/2024 | View on chart |
| EHC | ▼ Sell | Open Market | 44,976 | $3.7M | 4/30/2024 | View on chart |
| EHC | ▲ Buy | Grant | 74,711 | $0 | 2/28/2024 | View on chart |
| EHC | ▲ Buy | Grant | 14,789 | $0 | 2/28/2024 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 2,895 | $218K | 2/25/2024 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 2,256 | $170K | 2/24/2024 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 2,487 | $187K | 2/23/2024 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 25,159 | $1.7M | 1/2/2024 | View on chart |
| EHC | ▲ Buy | Option Exercise | 25,330 | $673K | 8/16/2023 | View on chart |
| EHC | ▼ Sell | Open Market | 25,330 | $1.8M | 8/16/2023 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 2,895 | $174K | 2/27/2023 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 2,256 | $136K | 2/24/2023 | View on chart |
| EHC | ▲ Buy | Grant | 16,824 | $0 | 2/23/2023 | View on chart |
| EHC | ▲ Buy | Grant | 61,503 | $0 | 2/23/2023 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 2,100 | $132K | 2/21/2023 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 14,576 | $872K | 1/3/2023 | View on chart |
| EHC | ▲ Buy | Option Exercise | 20,449 | $410K | 8/17/2022 | View on chart |
| EHC | ▼ Sell | Open Market | 20,449 | $1.1M | 8/17/2022 | View on chart |
| EHC | ▲ Buy | Grant | 16,258 | $0 | 2/25/2022 | View on chart |
| EHC | ▲ Buy | Grant | 31,730 | $0 | 2/25/2022 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 1,873 | $123K | 2/24/2022 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 3,782 | $249K | 2/22/2022 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 11,327 | $739K | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Encompass Health Sets Q3 2026 Earnings Call Date
Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.
Encompass Health Sets Q3 2026 Earnings Call Date. Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.